Comparative Pharmacology
Head-to-head clinical analysis: POLARAMINE versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLARAMINE versus PROMETHAZINE HYDROCHLORIDE.
POLARAMINE vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, blocking the effects of histamine in the respiratory tract, vasculature, and gastrointestinal tract.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
4-8 mg orally every 6-8 hours; maximum 24 mg/day.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 20-25 hours (range 14-36 hours). Clinical context: Supports once-daily dosing for chronic allergic symptoms; accumulation possible with hepatic impairment.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Primarily renal (40-60% as unchanged drug and metabolites), with minor biliary/fecal elimination
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic